2-Fluoro-N-(4-{3-[1-(4-fluoro-phenyl)-ethyl]-thioureido}-3-trifluoromethyl-phenyl)-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Fluoro-N-(4-{3-[1-(4-fluoro-phenyl)-ethyl]-thioureido}-3-trifluoromethyl-phenyl)-benzamide
• 英文别名: 2-fluoro-N-[4-[1-(4-fluorophenyl)ethylcarbamothioylamino]-3-(trifluoromethyl)phenyl]benzamide
• 化学式: C₂₃H₁₈F₅N₃OS
• 分子量: 479.5
• InChiKey: NVOHODKAPMAEDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  85.2
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] THIOUREA INHIBITORS OF HERPES VIRUSES<br/>[FR] THIO-UREES INHIBITRICES DES VIRUS DE L'HERPES
  申请人：AMERICAN HOME PROD

  公开号：WO2000034238A1

  公开（公告）日：2000-06-15

  Compounds of formula (I), wherein R1-R5 are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 carbon members, aryl, heteroaryl, halogen, -CN, -NO2, -CO2R6, -COR6, -OR6, -SR6, -SOR6, -SO2R6, -CONR7R8, -NR6N(R7R8), -N(R7R8) or W-Y-(CH2)n-Z provided that at least one of R1-R5 is not hydrogen; or R2 and R3 or R3 and R4, taken together form a 3 to 7 membered heterocycloalkyl or 3 to 7 membered heteroaryl; R6 and R7 are independently hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, or aryl; R8 is hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 members, aryl or heteroaryl, or R7 and R8, taken together may form a 3 to 7 membered heterocycloalkyl; R9-R12 are independently hydrogen, alkyl of 1 to 4 carbon atoms, perhaloalkyl of 1 to 4 carbon atoms, halogen, alkoxy of 1 to 4 carbon atoms, or cyano, or R9 and R10 or R11 and R12 may be taken together to form aryl of 5 to 7 carbon atoms; provided that at least one of R9-12 is not hydrogen; W is O, NR6, or is absent; Y is -(CO)- or -(CO2)-, or is absent; Z is alkyl of 1 to 4 carbon atoms, -CN, -CO2R6, COR6, -CONR7R8, -OCOR6, -NR6COR7, -OCONR6, -OR6, -SR6, -SOR6, -SO2R6, SR6N(R7R8), -N(R7R8) or phenyl; G is aryl or fused bicyclic heteroaryl; and X is a bond, -NH, alkyl of 1 to 6 carbon atoms, alkenyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, thioalkyl of 1 to 6 carbon atoms, alkylamino of 1 to 6 carbon atoms, or (CH)J; J is alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl or benzyl; and n is an integer from 1 to 6, in the treatment of diseases associated with herpes viruses including human cytomegalovirus, herpes simplex viruses, Epstein-Barr virus, varicella-zoster virus, human herpesviruses-6 and -7, and Kaposi herpes virus.

  化合物的公式（I），其中R1-R5独立地选择自氢，1至6个碳原子的烷基，2至6个碳原子的烯基，2至6个碳原子的炔基，1至6个碳原子的全氟烷基，3至10个碳原子的环烷基，3至10个碳成员的杂环烷基，芳基，杂芳基，卤素，-CN，-NO2，- R6，-COR6，-OR6，-SR6，-SOR6，-SO2R6，-CONR7R8，-NR6N（R7R8），-N（R7R8）或W-Y-（CH2）n-Z，其中至少有一个R1-R5不是氢; 或者R2和R3或R3和R4，一起形成3至7个成员的杂环烷基或3至7个成员的杂芳基; R6和R7独立地为氢，1至6个碳原子的烷基，1至6个碳原子的全氟烷基或芳基; R8为氢，1至6个碳原子的烷基，1至6个碳原子的全氟烷基，3至10个碳原子的环烷基，3至10个成员的杂环烷基，芳基或杂芳基，或者R7和R8一起可以形成3至7个成员的杂环烷基; R9-R12独立地为氢，1至4个碳原子的烷基，1至4个碳原子的全氟烷基，卤素，1至4个碳原子的烷氧基或氰基，或者R9和R10或R11和R12可以一起形成5至7个碳原子的芳基; 提供至少一个R9-12不是氢; W为O，NR6或不存在; Y为-(CO)-或-(CO2)-，或不存在; Z为1至4个碳原子的烷基，-CN，- R6，COR6，-CONR7R8，-OCOR6，-NR6COR7，-OCONR6，-OR6，-SR6，-SOR6，-SO2R6，SR6N（R7R8），-N（R7R8）或苯基; G为芳基或融合的双环杂芳基; X为键，-NH，1至6个碳原子的烷基，1至6个碳原子的烯基，1至6个碳原子的烷氧基，1至6个碳原子的硫代烷基，1至6个碳原子的烷基氨基或（CH）J; J为1至6个碳原子的烷基，3至7个碳原子的环烷基，苯基或苄基; n为1至6的整数，在治疗与疱疹病毒相关的疾病中，包括人类巨细胞病毒，单纯疱疹病毒，EB病毒，水痘-带状疱疹病毒，人类疱疹病毒6和7以及卡波西疱疹病毒。
• THIOUREA INHIBITORS OF HERPES VIRUSES
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP1137632A1

  公开（公告）日：2001-10-04
• US6207715B1
  申请人：——

  公开号：US6207715B1

  公开（公告）日：2001-03-27
• [EN] NEW ALKYNYLATED QUINAZOLIN COMPOUNDS AS MMP-13 INHIBITORS<br/>[FR] NOUVEAUX COMPOSES DE QUINAZOLINE ALCYNYLES UTILISES COMME INHIBITEURS DE LA MMP-13
  申请人：WARNER LAMBERT CO

  公开号：WO2004007469A1

  公开（公告）日：2004-01-22

  A compound selected from those of formula (I) wherein W1 represents O, S, or -NR3 in which R3 represents hydrogen, alkyl, OH or CN; W2 represents a group selected from hydrogen, CF3, NH2, monoalkylamino, dialkylamino, alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkylalkyl, heterocycle, these groups being optionally substituted, or W1 and W2 form together a group of formula -N=X4-W3- as defined in the description, X1, X2 and X3 represent N or C optionally substituted, n is 0 to 8, Z represents -CR12R13, wherein R12 and R13 are as defined in the description, A represents a ring system, the groups R2 represent hydrogen or various chemical groups as defined in the description, q is 0 to 7; R1 represents hydrogen, alkyl, alkenyl, alkynyl, or a ring system, and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.